Kornimate/medical-research-clean huggingface dataset:
investigating the role of mucin and mucin glycosylating enzymes in nasopharyngeal carcinoma and salivary gland cancer and their correlation with clinical prognosis

Conditions: Salivary Gland Cancer; Nasopharyngeal Carcinoma

Summary: nasopharyngeal carcinoma (npc) is the tenth leading cancers in taiwan and investigating its biomarker is important for understanding the mechanism of its pathogenesis.

npc is the tenth leading cancers in taiwan and investigating its biomarker is important for understanding the mechanism of its pathogenesis.

Eligibility criteria:
inclusion criteria: * npc and salivary gland tumor diagnosed and treated in htuh exclusion criteria: * previous treatment or surgery

Keywords: biomarker
glutamine and insulin sensitivity in type i diabetes

Conditions: Type I Diabetes Mellitus

Summary: insulin is crucial to help the body metabolize ('burn') sugar (glucose). even though juvenile (type 1) diabetes (t1d) is primarily due to the lack of insulin, patients with t1d tend to become less sensitive to insulin, particularly during adolescence. the overall objective of this project is to gain further insight into the possible benefits of supplementation with glutamine (gln), a natural dietary amino acid, enhancing insulin sensitivity in adolescents with t1d. to elucidate the impact of glutamine, the investigators will use a method called the 'euglycemic, hyperinsulinemic clamp': it consists of giving an iv drip of insulin, while the drop in blood sugar is prevented by giving variable, precisely measured amounts of glucose by vein: the amount of glucose required to prevent a drop in blood sugar reflects the body's sensitivity to insulin. the investigators will also give an iv drip of glucose and arginine (a building block of protein) 'tagged' with non-radioactive isotopes to better understand how glutamine may work. this procedure will be performed in 2 groups of 10 adolescents in the morning either after a strenuous exercise performed the previous afternoon (group 1; n=10), or after a sedentary day (group 2; n=10). each subject will be studied twice, once after taking oral gln, once after placebo, in separate clinical research center (crc) admissions a few weeks apart, in random order. should the investigators hypothesis prove to be true, it would warrant long term studies to determine whether sustained dietary gln supplementation can decrease insulin requirements and ultimately improve diabetes control in teenagers with t1dm, if successful, this approach could potentially have a significant positive impact in terms of adolescent health.


Eligibility criteria:
inclusion criteria: * type i diabetes diagnosed for \> 12 months. * minimal weight of 40 kg * tanner stage iv or beyond * all insulin programs, including intermediate/short acting insulins, lantus/detemir and short acting insulin or insulin pump therapy. * hba1c between 7.5 and 10% * bmi between 10th to 85th percentile * patients on stable thyroid replacement therapy will be allowed to participate. exclusion criteria: * celiac disease (any patient with history of positive serology or consuming a gluten-free diet) * cystic fibrosis * chronic steroid therapy * chronic medications that may interfere with glucose metabolism or liver function * history of mental retardation * presence of diabetic complications * positive pregnancy test * presence of significant anemia (hb\<11 g/dl) * presence of intercurrent infection

Keywords: type i diabetes insulin resistance glutamine amino acids glucagon like peptide 1 glutathione citrulline arginine nitric oxide
extracorporeal membrane oxygenation (ecmo) in non-intubated patients with acute respiratory distress syndrome (ards)

Conditions: ARDS

Summary: proof-of-concept study addressing the feasibility of awake ecmo (v/v) in patients with acute respiratory failure

pilot study in 6 patients with ards addressing the use of awake veno-venous ecmo to avoid endotracheal intubation and mechanical ventilation

Eligibility criteria:
inclusion criteria: * patients aged 18-75 yrs with acute respiratory failure due to ards or pneumonia fulfilling standard criteria for endotracheal intubation * severe and progressive hypoxemia, i.e. pao2 \ 10 l/min not tolerating noninvasive ventilation, or * pao2/fio2 \< 200 not improving or deteriorating on noninvasive ventilation, or * respiratory distress and hypoxemia not fulfilling the criteria above with clinical impression of the icu attending that intubation and mechanical ventilation are mandated * patient considered eligible by at least two investigators of this study exclusion criteria: * patient does not fulfill the inclusion criteria * uncontrolled malignancy * severe and untreatable coagulation or bleeding disorders (inr \> 2,0; aptt \> 60s, platelet count \< 50.000/µl, all after substitution) * stroke within the past 3 months * uncontrolled sepsis or septic shock * multiorgan failure involving \> 2 organ systems * norepinephrine dose \> 1 mg/h * hyperdynamic circulation, indicated by cardiac index \> 4.0 l/min/m2 (measured by picco or swan-ganz catheter), or svo2 \> 80% * cardiac pump failure, indicated by echocardiography (ef \ 9,0 g/dl and sao2 \> 90%), or the need for inotropes (dobutamine, epinephrine, levosimendan) * clinical or echocardiographic signs of pulmonary hypertension with right ventricular dysfunction * apache-ii score15 \< 25 * other conditions suggesting that the patient would benefit from intubation and mechanical ventilation * severe neurological disorders * estimated mortality due to severity of acute and/or underlying illness \> 50%

Keywords: ards
a study of regn2810 and ipilimumab in patients with lung cancer

Conditions: Advanced Non-Small Cell Lung Carcinoma

Summary: the primary objective of the study is to compare the objective response rate (orr) of high dose cemiplimab (hdregn2810) and standard dose cemiplimab plus ipilimumab combination therapy (sdregn2810/ipi) to the orr of standard dose cemiplimab (sdregn2810) in the second-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (nsclc), in patients whose tumors express programmed cell death ligand 1 (pd-l1) in \<50% of tumor cells.


Eligibility criteria:
key inclusion criteria: 1. patients with histologically or cytologically documented squamous or non-squamous nsclc who either have stage iiib or stage iiic disease who are not candidates for treatment with definitive concurrent chemo-radiation or have stage iv disease. patients must have pd after receiving one prior line of chemotherapy treatment for advanced nsclc. 2. availability of an archival or on-study obtained formalin-fixed, paraffin-embedded tumor tissue biopsy sample 3. biopsy evaluable for expression of pd-l1 as determined by a pd-l1 immunohistochemistry (ihc) pharma diagnostic test (pharmdx) assay performed by a central laboratory 4. at least 1 radiographically measureable lesion by computed tomography (ct) per recist 1.1 criteria 5. eastern cooperative oncology group (ecog) performance status of ≤1 key exclusion criteria: 1. patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime 2. active or untreated brain metastases or spinal cord compression 3. patients with tumors tested positive for epidermal growth factor receptor (egfr) gene mutations, anaplastic lymphoma kinase (alk) gene translocations, or c-ros oncogene receptor tyrosine kinase (ros1) fusions 4. encephalitis, meningitis, or uncontrolled seizures in the year prior to randomization 5. history of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years 6. ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest a risk of immunerelated treatment-emergent adverse events (irteaes) 7. patients with a condition requiring corticosteroid therapy (\>10 mg prednisone/day or equivalent) within 14 days of randomization note: other protocol defined inclusion/exclusion criteria apply.

Keywords: advanced non-squamous nsclc advanced squamous nsclc
behavioral relaxation approaches for insomnia in pregnant patients

Conditions: Sleep Initiation and Maintenance Disorders; Pregnancy Related

Summary: this study will evaluate the effect of a simplified behavioral relaxation intervention to improve insomnia in pregnant women

this is a randomized, 60-day research study that is evaluating the effect of a simplified behavioral relaxation intervention in pregnant and postpartum patients aimed to improve their insomnia symptoms. the investigators will be enrolling a total of 20 patients who indicate self-reported insomnia symptoms.

Eligibility criteria:
inclusion criteria: * age between 18 and 55 * in second or third trimester of pregnancy (gestation weeks 18-32) * able to speak, read and write fluent english * has regular access to a smartphone and/or smart tablet * sleep onset latency (sol) or nocturnal awakening need be 30 min or more for ≥3 nights/week, must persist for at least 1 month exclusion criteria: * participants with fixed night shift work between midnight and 5 am, or rotating work schedules requiring night shifts during the study period. * medical or other factors that, in the opinion of the study research team, would interfere with their ability to participate in the intervention (such as inability to participate in the art due to blindness)
maintaining fitness during neo-adjuvant chemotherapy for oesophago-gastric cancer: a feasibility study

Conditions: Esophageal Adenocarcinoma; Gastric Adenocarcinoma

Summary: feasibility study to investigate the utility of a simple, home-based, exercise intervention during and after neo-adjuvant chemotherapy but prior to surgery for esophageal and gastric adenocarcinoma.

the principle aim of this study is to test the feasibility of utilising a home-based 'prehabilitation' exercise regimen in oesophago-gastric patients during preoperative chemotherapy and the period leading up to surgical resection. the investigators also hope to explore secondary outcomes of such a regimen, such as maintenance of fitness, the incidence of sarcopenia, muscle function and the outcomes of therapy. the investigators will explore the added value of blood-borne frailty biomarkers to objectively measure changes in physiology during neo-adjuvant chemotherapy (nac). this will be tested using cpet, ct measured sarcopenia, grip strength and a small panel of biomarkers as secondary outcome and exploratory measures. thus the main question is: 'will patients participate in a home-based exercise programme during and after nac for oesophago-gastric cancer?'

Eligibility criteria:
inclusion criteria: * operable adenocarcinoma of the oesophagus, oesophago-gastric junction and stomach (locally advanced adenocarcinoma with planned preoperative chemotherapy, t3+, t1/2 n+) * planned preoperative chemotherapy with ecx, ecx variant or flot chemotherapy * age \>18 * ability to complete cpet * ability to consent to study and carry out the planned intervention. exclusion criteria: * standard contraindications to cpet testing as defined by ats guidance * orthopaedic limitations to cpet and / or daily exercise, for example, amputation, severe knee or hip disease. * inoperable cancer at initial screening mdt * planned non-surgical treatment with either radiotherapy or combined chemoradiotherapy
zink and bone strength

Conditions: Coxarthrosis; Fracture of Femoral Neck

Summary: zink and bone strength

blood- and urine samples collected from 20 oa patients and 20 osteoporosis patients who all had a hip-replacement. all patients were evaluated by dexa-scanning.

Eligibility criteria:
inclusion criteria: postmenopausal women with osteoarthrosis or femoral neck-fracture i one hip exclusion criteria: pathology or prosthesis in contralateral hip
study to test an approved product in the early treatment of migraine (0462-065)

Conditions: Migraine

Summary: the purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine while the pain is still mild.


Eligibility criteria:
inclusion criteria: * 6-month history of migraine * migraine attacks typically mild when they begin with 1-4 migraine attacks per month exclusion criteria: * heart disease * high blood pressure
effectiveness of two exercise protocols in the treatment of patients with patellar tendinopathy

Conditions: Patellar Tendinopathy

Summary: patellar tendinopathy is characterized by anterior pain in the knee, due to the great demand imposed on the extensor mechanism of the knee. evidence shows that the most appropriate treatment for this condition is the conservative treatment, through strengthening with eccentric exercises. however, a recent editorial proposes a new treatment protocol based on concentric and eccentric exercises, with the initial prescription of isometric exercises. the hypothesis of this study is that the protocol is as good as the eccentric exercises, generating less pain.


Eligibility criteria:
inclusion criteria: * patients with chronic unilateral patellar tendinopathy confirmed by the reproduction of the pain during the palpation test in the region of the lower pole of the patella * presence of pain for three months or more * both genders * body mass index less than 30 kg/m² * age between 18 and 40 years * practice of physical activity on a regular basis * pain intensity ≥ 3 points on the pain numerical rating scale in the anterior region of the knee, specifically in the region of the lower pole of the patella when performing squatting, jumping or activities with change of direction * score \< 80 points on the victorian institute of sport assessment-patella (visa-p) * blazine functional scale between 1 and 3 exclusion criteria: * patients who have previous pain in the knee that does not correspond to patellar tendinopathy * previous rupture of the patellar tendon (blazin functional scale at level 4) * previous surgery or infiltration of the patellar tendon in the last six months * inflammatory diseases * diabetes mellitus * lower limbs injuries * other chronic pain conditions that prevent exercise, such as severe hip and knee osteoarthrosis and joint fractures.

Keywords: exercise therapy heavy slow resistance program rehabilitation
the effects of video modeling of audiological testing on pediatric patient compliance

Conditions: Autism

Summary: the purpose of the current study is to determine if pre-exposure through video modeling will enhance testing compliance in a population of children who are receiving a diagnostic evaluation for autism.

the purpose of the current study is to determine if pre-exposure through video modeling will enhance testing compliance in a population of children who are receiving a diagnostic evaluation for autism. another purpose of this study is to determine if pre-exposure to the test setting can increase the compliance on individual test measures. to test the central hypothesis and accomplish the study objective, 2 aims guide the proposed study. 1. determine the extent to which pre-exposure to expectations and tasks that occur during the audiological evaluation will increase audiological testing compliance. hypothesis: children receiving the intervention video, which will model what they will experience during the audiological evaluation, will show greater compliance during the evaluation than children who receive the placebo video. 2. determine the extent to which enhanced testing compliance will increase the number of test measures obtained during an audiological evaluation. hypothesis: children who are more compliant during the audiological evaluation will allow the audiologist to obtain more test measures in a single appointment than the children who are less compliant.

Eligibility criteria:
inclusion criteria: inclusion criteria: * child must have chronological age of less than 36 months * participation in the northwestern university center for audiology, speech, language, and learning (nucasll) developmental diagnostic program (ddp) * a parent or caregiver who is willing to watch the intervention video, bring the child to/ participate in the audiological evaluation, and fill out a brief survey prior to and following the appointment, and * parent must understand english and speak english to their child. exclusion criteria: * none

Keywords: autism audiology video modeling testing compliance
the effectiveness of assertive community treatment on schizophrenic patients

Conditions: Schizophrenia

Summary: assertive community treatment (act) is a community-based, patient-centered, and rehabilitation-oriented model based on multidisciplinary service teams. it has been proved to be suitable for the management of patients with severe mental disorder in the community. in this study, we aimed to investigate the effectiveness of act in an urban district of shanghai with a larger sample size and a 24-month duration of follow up. we hypothesized that patients assigned into act would show better improvement in psychiatric symptoms and social function.

assertive community treatment (act) is a community-based, patient-centered, and rehabilitation-oriented model based on multidisciplinary service teams. it has been proved to be suitable for the management of patients with severe mental disorder in the community. in this study, we aimed to investigate the effectiveness of act in an urban district of shanghai with a larger sample size and a 24-month duration of follow up. we hypothesized that patients assigned into act would show better improvement in psychiatric symptoms and social function.the study protocol was approved by the institutional review board in shanghai mental health center. aim of the study: 1.1 to explore the effectiveness of assertive community treatment in patients with schizophrenia. 1.2 the patients were followed up for 24 months to explore the duration of act. introduction of the study: patients who previously diagnosed as schizophrenia according to international classification of diseases 10th revision (icd-10) in the psychiatric hospitals would receive basic public health service in the community. the selected schizophrenic patients were randomly assigned into intervention group and control group by a computer randomization algorithm. during the following 2 years, the control group received basic public health services in the community while the intervention group received act. clinical assessments were conducted at baseline and every 6 months till the end of the 2-year study. a single-blind method was used, in which all the assessments were independently completed by trained psychiatrists who didn't know the grouping.the positive and negative symptoms scale (panss) and the personal and social performance scale (psp) were measured at baseline and every 6 months during the study.

Eligibility criteria:
inclusion criteria: 1. aged between 18 and 50 years old; 2. course of disease between 2 and 20 years; 3. living with family members who can function as their caregivers; 4. disease condition was stable and the total score of the positive and negative symptoms scale (panss) is less than 60. exclusion criteria: 1. women during pregnancy; 2. having mental retardation or psychoactive substance-induced mental disorders; 3. having serious physical condition.

Keywords: schizophrenia assertive community treatment community rehabilitation
osseodensification by densah burs with activated plasma albumin gel for sinus lifting with simultaneous implant placement

Conditions: Bone Loss, Alveolar

Summary: aim of the current study is to evaluate clinically and radiographically transcrestal sinus lifting with densah burs with the use of activated plasma albumin gel associated with simultaneous implant placement.


Eligibility criteria:
inclusion criteria: * patient with missing maxillary premolars and molars. * vertical bone height of 3-5 mm. * good oral hygiene. * non smokers. exclusion criteria: * bad oral hygiene. * presence of infection or periapical lesions in adjacent teeth. * acute maxillary sinusitis. * bruxism or clenching. * medically compromised patients with a condition that affects the procedure (patients with bone diseases such as osteogenesis imperfecta and polyarthritis and patients on radiotherapy and chemotherapy)

Keywords: transcrestal sinus lifting
the clinical outcome of bicri in the treatment of chondral and osteochondral lesions

Conditions: Articular Cartilage Disorder of Knee

Summary: based on the previous successful experiences, the investigators like to extend our patient population. in this study, the investigators aim to determine the safety and effectiveness of the biphasic cartilage repair implant (bicri) in the treatment of chondral and osteochondral lesions of the knee, including but not limited to more than one (1) lesion and the lesion that had been treated with microfracture or mosaicplasty but failed.

patients who qualify for this trial and who are interested in participating will be consented using an institutional review board (irb) approved informed consent. once a patient has signed the informed consent form he/she is considered enrolled in the trial. if during surgery the size of lesion is found to meet exclusion criteria, the subject will be considered withdrawn (screen failure) from the trial. clinical trial eligibility should be determined by confirmation that the patient meets the criteria included in the protocol. standard arthroscopic technique should be used to fully assess the joint and determine if the chondral or osteochondral defect is appropriate for inclusion in the study. through arthroscopic examination after initial debridement, the investigator should use his best judgment to estimate the size of the lesion, and the number of bicri to be applied. plain radiographs and mri prior to 6-month (inclusive) visit will be performed according to routine clinical practice; however, 12-month and 24-monthpostoperative images should be done for study outcome evaluation

Eligibility criteria:
inclusion criteria: 1. - age between 16\~65 (inclusive) years old presenting with either symptomatic chondral or osteochondral lesion of knee requiring primary surgical intervention. the lesions may include but not limited to following conditions: * multiple lesions * lesion that had been treated with microfracture or mosaicplasty but failed. 2. the index lesion is icrs grade 3-4 lesion, outerbridge grade 4, or ocd grades 3-4 3. willing and able to consent in wiring to participate in the study exclusion criteria: * 1. rheumatoid arthritis and other inflammatory arthritis 2. the index cartilage lesion requires more than 3 (exclusive) implants 3. skeletally immature (epiphyses are not closed based on x-ray) 4. concomitant comorbidities 5. local or systemic infection, not including asymptomatic urinary tract infection if treated with antibiotics preoperatively 6. pregnancy or breast feeding 7. prisoner 8. patient is actively participating in another medical device, drug, or biologic investigation (active defines as within the last 30 days prior to signing the consent form) 9. any condition that is not suitable to participate in the study based on the physician's judgement